Impact of Systolic Blood Pressure on the Safety and Tolerability of Initiating and Up-Titrating Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction: Insights from the TITRATION Study

Abstract

The majority of patients (>80%) with SBP of ≥100 mmHg achieved and maintained the target dose of sacubitril/valsartan if the treatment was titrated gradually. These findings suggest that low SBP should not prevent clinicians from considering the initiation of sacubitril/valsartan.